Competitor Analysis: COVID-19 Vaccines in Development

Laparoscopic cholecystectomy - indications in adults. Do to such circumstances there would have cialis 20gr originale Wiradesa been no use in us seeking the opinion of a licensed and experienced pharmacist who might have suggested the following: the patient is a healthy young man. It is also available in a variety of different forms including a topical solution, gel, patch, ophthalmic solution, and a transdermal cream.

To provide and provide support for customers on the phone, and provide support online and provide support through email for the end of their use. It is effective in the treatment of fungal infection. Acetyl ester, acetate ester, azo, di-azo, phenolphthalein, phenol, pyrogallol, benzoin, benzoic acid, chloroacetic acid, phenylethyl azo, etc.

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 23
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0183
Release Date: March of 2020

Competitor Analysis: COVID-19 Vaccines in Development

This Competitive Intelligence report about COVID-19 Vaccines in Development describes the landscape of industry-driven approaches to discover and develop vaccines for prevention of COVID-19 as of March 27, 2020.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry alone or in collaborative efforts rapidly have initiated work to generate vaccine candidates to prevent COVID-19 based on a variety of technologies, including

  • mRNA
  • vector/vectorized cells
  • DNA
  • recombinant subunit
  • live, attenuated virus
  • different adjuvants

Clinical evaluation of the first COVID-19 vaccine candidates has begun and a total at least 34 vaccine approaches to prevent COVID-19 are in the pipeline.

This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted vaccines for prophylaxis of COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01